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We investigated the activities of telavancin and vancomycin against biofilm-producing Staphylococcus and
Enterococcus strains. At clinically attainable concentrations, telavancin was active against bacteria embedded
in biofilm (minimal biofilm eradication concentration [MBEC], 0.125 to 2 g/ml) and inhibited biofilm
formation at concentrations below the MIC. Vancomycin did not demonstrate the same activity (MBEC, >512
g/ml) against Staphylococcus aureus and Enterococcus faecalis. Telavancin may have a unique role in biofilm-
associated infections.
Staphylococci and enterococci account for a large propor-
tion of hospital-acquired infections, especially among patients
with indwelling devices (17). These infections are often caused
by biofilm-producing strains which are difficult to eradicate and
which may cause bacteremia and metastatic infections (30).
Telavancin is a new lipoglycopeptide antimicrobial agent
with a core chemical structure similar to that of vancomycin yet
modified to include a lipophilic side chain (15). Telavancin
possesses a second mechanism of action that causes rapid
depolarization and loss of the functional integrity of the bac-
terial membrane (1, 12). These two mechanisms of action may
be implicated in the lower range of methicillin (meticillin)-
resistant Staphylococcus aureus (MRSA) MICs observed with
telavancin (MIC range, 0.06 to 1.0 g/ml) compared to vanco-
mycin (MIC range, 0.5 to 2 g/ml) (8, 13).
Previous reports have suggested that telavancin is more ef-
fective than vancomycin against biofilm-forming S. aureus in a
pharmacokinetic filter model (9). We compared telavancin and
vancomycin activities by using previously described in vitro
biofilm activity assays. The first assay evaluated each agent’s
activity in a preformed biofilm by using both a modified version
and the standard version of the Calgary Biofilm Pin Lid Device
(CBPD) (3, 14). The second assay evaluated activity in
preventing biofilm formation by planktonic isolates (14).
(This work was presented in part at the 48th annual Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, Washington, DC, 24 to 28 October 2008.)
Telavancin and vancomycin analytical powder, freshly pre-
pared each day, was obtained from Astellas Pharmaceuticals,
Inc. (Audubon, PA), and Sigma-Aldrich (St. Louis, MO), re-
spectively. Well-characterized biofilm-producing reference
strains of S. aureus (ATCC 35556), Staphylococcus epidermidis
(RP62A; ATCC 35984), and Enterococcus faecalis (ATCC
29212; vancomycin susceptible) were evaluated. A stable,
slime-negative mutant, M7, from wild-type S. epidermidis
RP62A served as a control (21). We also evaluated three ran-
domly selected, biofilm-producing clinical isolates (methicillin-
susceptible S. aureus [MSSA] L2, and MRSA L32 and L83)
previously obtained from patients with catheter-related blood-
stream infections at the Providence Veterans Affairs Medical
Center.
The medium used for biofilm growth was Bacto tryptic soy
broth (TSB; Becton Dickinson, Sparks, MD) plus 1% glucose
and 2% NaCl (14). All assays were run in quadruplicate, and
cultures were incubated at 35°C. Conventional MICs and min-
imal bactericidal concentrations (MBCs) were determined in
duplicate by using Clinical and Laboratory Standards Institute
(CLSI) guidelines (5, 6).
We used a modified version of the CBPD to determine the
antimicrobial susceptibility of bacteria embedded in a 24-h
biofilm to determine the minimum biofilm inhibitory concen-
tration (MBIC) and the minimum biofilm eradication concen-
tration (MBEC) (3). Briefly, a starting inoculum of 7 log10
CFU/ml was established by the direct colony suspension
method from a 24-h tryptic soy agar (TSA; Becton Dickinson,
Sparks, MD) plate. This inoculum was then standardized with
McFarland standards and validated by determination of viable
counts on TSA plates. Biofilms developed on the pin lid
(Immuno TSP; Nunc, Roskilde, Denmark) submerged in the
inoculated broth at 35°C for 24 h on a rocking table (Boekel
Shake and Bake; Boekel Scientific; Feasterville, PA). The pin
lid was then rinsed three times in 1 phosphate-buffered saline
(PBS) to remove sessile bacteria before placement into fresh
uninoculated broth containing serial dilutions of each antibi-
otic and incubated for 24 h at 35°C. The next day, the pin lid
was removed and the MBIC was recorded and defined as the
last well in which there is no visible growth after incubation in
the presence of biofilm and antibiotic. Next, to obtain the
MBEC, the pin lid was rinsed in 1 PBS and then sonication
(10 min) was performed on a low-output sonicator (45 Hz) in
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order to disperse the bacteria from the pin surface. After
sonication, the broth was vortexed for 30 s. The fluid was
serially diluted and plated in duplicate on TSA, and the num-
ber of CFU per milliliter was determined. The limit of detec-
tion was 2.4 CFU/ml. Viable counts were also obtained by
measuring the turbidity at 570 nm (A570) on a 96-well plate
reader.
Quantification of biofilm formation in the presence of tela-
vancin (0 to 16 g/ml) and vancomycin (0 to 16 g/ml) was
conducted with a previously described colorimetric microtiter
plate assay (4, 14, 24). Wells with sterile TSB alone served as
negative controls, and the mean optical density (OD) values of
these wells was subtracted from the OD values of the test wells.
Following incubation, the liquid was gently aspirated and
replaced with sterile PBS (pH 7.3). Each well was rinsed three
times and air dried. Adherent bacteria were then stained with
crystal violet. The OD at 570 nm (OD570) of stained adherent
bacterial films was read with a spectrophotometer (Synergy 2;
Bio-Tek Instruments, Inc., Winooski, VT). The ODs of bacte-
rial films were classified into nonadherent, weakly, moderately,
and strongly adherent categories based on multiples of the OD
readings as described by Stepanovic´ et al. The test was carried
out in quadruplicate. Results were averaged, and standard
deviations were calculated (23).
Among planktonic bacteria, the ranges of telavancin MICs
and MBCs were 0.03 to 0.25 and 0.125 to 1 g/ml, respectively.
The ranges of vancomycin MICs and MBCs were 1 to 2 and 2
to 16 g/ml, respectively (Table 1). When evaluating the ac-
tivity of sessile bacteria seeding the medium from formed bio-
film, the MBICs of telavancin and vancomycin were 0.25 to 1
and 4 to 16 g/ml, respectively (Table 1). Overall, the telavan-
cin and vancomycin MBICs for each bacterial isolate were the
same as the corresponding MICs or up to 3 dilutions higher.
As in previous reports, vancomycin demonstrated no activity
against bacteria embedded in a biofilm produced by S. aureus
(MBEC of 512 g/ml; Table 1) (3). However, it is interesting
that telavancin demonstrated activity against these bacteria
with MBECs of 0.125 to 2 g/ml. Thus, clinical doses of tela-
vancin (93% of the drug is protein bound; the calculated max-
imum concentration of unbound drug in serum is 6.1 g/ml)
will exceed the MBIC and MBEC and should result in activity
against bacteria embedded in a biofilm.
To quantify biofilm formation in the presence of each agent
(Fig. 1), we first characterized the biofilm production of each
isolate in the absence of any drug. Established biofilm produc-
ers MSSA (ATCC 35556) and S. epidermidis (ATCC 35984)
demonstrated the most robust slime formation at an OD570 of
1.4  0.23 (strongly adherent). The clinical isolates consis-
tently produced biofilm (OD570 of 1.0  0.41; moderately
adherent), and the non-biofilm-forming control isolate (M7)
did not produce biofilm (OD570 of 0.19 0.008; nonadherent).
Telavancin inhibited biofilm formation at concentrations be-
low each isolate’s respective MIC. In contrast, vancomycin
inhibited biofilm formation at concentrations at or above each
isolate’s respective MIC.
At clinically achievable concentrations, telavancin was active
against bacteria embedded in biofilm (MBEC) and bacteria
seeding from a formed biofilm mass (MBIC) and inhibited
biofilm development (Fig. 1). Vancomycin did not demon-
strate this same activity in a formed biofilm at clinically achiev-
able concentrations.
Telavancin’s activity against bacteria embedded in biofilm
may be explained by its chemical composition as a lipoglyco-
peptide (15), its multiple mechanisms of action including dis-
ruption of bacterial membrane function (12), and its activity
against stationary bacteria (10).
Telavancin is a semisynthetic derivative of the glycopeptide
vancomycin; however, it differs from vancomycin by additional
hydrophobic and hydrophilic moieties (15). Specifically, tela-
vancin contains a lipophilic decylaminoethyl side chain at-
tached to the vancosamine sugar, as well as a hydrophilic
[(phosphonomethyl)aminomethyl] group on the 4 position of
amino acid 7 (15). These substituents in the molecule classify
this agent as a lipoglycopeptide. Telavancin has two proposed
mechanisms of action. The first mechanism is similar to that
established for vancomycin and involves telavancin binding in
a highly specific, noncovalent fashion to the terminal D-Ala–
D-Ala stem peptides. As a consequence of this binding, the
cross-linking step in the cell wall is inhibited (12). The second
proposed mechanism of action involves depolarization of the
bacterial membrane. This results in disruption of the func-
tional integrity of the bacterial membrane, causing rapid, con-
TABLE 1. Susceptibility testing results for planktonic and adherent
(biofilm) strains
Antibiotic and strain
Planktonic
organisms tested
by CLSI
guidelines
MBIC
(g/ml)a for
sessile bacteria
seeding from
formed biofilm
MBEC (g/ml)
based on A570b
for CBPD
activity in
formed biofilmMIC
(g/ml)
MBC
(g/ml)
Telavancin
S. epidermidis M7
(non-BFc control)
0.125 0.125 0.5 0.5
S. epidermidis RP62A
(ATCC 35984)
0.125 0.125 0.5 1
S. aureus ATCC 35556 0.06 0.25 0.25 0.125
E. faecalis ATCC 29212 0.25 1 1 1
MSSA L2 (clinical
isolate)
0.06 0.125 1 1
MRSA L32 (clinical
isolate)
0.03 0.125 1 2
MRSA L83 (clinical
isolate)
0.06 0.125 0.25 1
Vancomycin
S. epidermidis M7
(non-BF control)
1 1 8 2
S. epidermidis RP62A
(ATCC 35984)
2 2 4 4
S. aureus ATCC 35556 1 2 16 256
Enterococcus faecalis
ATCC 29212
2 16 16 256
MSSA L2 (clinical
isolate)
2 2 16 256
MRSA L32 (clinical
isolate)
1 2 8 256
MRSA L83 (clinical
isolate)
2 2 4 256
a The values were obtained by determination of plate counts, and the limit of
detection was 2.4 CFU/ml.
b The values were obtained by measuring turbidity at 570 nm (A570) on a
96-well plate reader.
c BF, biofilm.
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centration-dependent depolarization of the plasma membrane,
increased permeability, and leakage of cellular ATP and K
(12).
Bacteria embedded within a biofilm are difficult to eradicate
due to a wide variation of nutrient gradients that slow or arrest
bacterial growth, protein synthesis, and other physiologic activi-
ties (29). Slow-growing or nongrowing bacteria sequestered in
biofilm are less susceptible to antibiotics by virtue of their reduced
growth rates (2, 29). Although telavancin has been shown to have
activity against stationary bacteria (10), the MBICs for sessile
bacteria seeding the medium from an established biofilm required
higher antimicrobial concentrations for inhibition compared to
the MICs for planktonic bacteria.
Telavancin exerts concentration-dependent killing, and the
pharmacodynamic index that best correlates with its antimicro-
bial effect is the area under the concentration-time curve over
24 h (AUC0-24) divided by the MIC (11). Maximal bacterial
killing is observed at a maximal concentration of the drug in
serum of 40 g/ml and with an AUC0-24/MIC ratio of 404 (18).
An achievable serum concentration of the clinically recom-
mended intravenous telavancin dose of 10 mg/kg is 87.5 g/ml,
with an expected AUC0-24 of 604 ml/h/kg (22). Since 93% of
the drug is protein bound, the calculated maximum concentra-
tion of unbound drug in serum is 6.1 g/ml and the unbound-
drug AUC is 42 ml/h/kg. Thus, clinical doses of telavancin (free
drug) will exceed the MBIC and MBEC and should have
activity against bacteria embedded in a biofilm.
Clinical data support the use of telavancin in the treatment
of complicated skin and soft-tissue infections and hospital-
acquired pneumonia infections (7, 25–27). Animal model data
suggest efficacy in the treatment of bacteremia, endocarditis,
meningitis, and pneumonia caused by gram-positive pathogens
(1, 16, 19, 20, 28). Our findings suggest that future use of
telavancin holds promise in treating infections caused by bio-
film-producing staphylococci and enterococci and that it
should be further evaluated for the treatment of biofilm-re-
FIG. 1. Effects of telavancin and vancomycin on biofilm formation. Biofilm-forming S. aureus, S. epidermidis, and E. faecalis strains were grown
in 96-well polystyrene plates exposed to increasing concentrations of telavancin or vancomycin. Results are averages of four duplicates  the
standard error of the mean. TSB, negative control wells containing TSB only; pos, positive control wells (no drug).
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lated infections such as salvaging colonized intravascular cath-
eters with antibiotic lock therapy.
We thank Suzanne Woodmansee for technical assistance.
This research was supported in part by an unrestricted, investigator-
initiated grant from Astellas Pharmaceuticals, Deerfield, IL.
REFERENCES
1. Attwood, R. J., and K. L. LaPlante. 2007. Telavancin: a novel lipoglycopep-
tide antimicrobial agent. Am. J. Health Syst. Pharm. 64:2335–2348.
2. Brown, M. R., D. G. Allison, and P. Gilbert. 1988. Resistance of bacterial
biofilms to antibiotics: a growth-rate related effect? J. Antimicrob. Che-
mother. 22:777–780.
3. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret.
1999. The Calgary Biofilm Device: new technology for rapid determination
of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771–
1776.
4. Christensen, G. D., W. A. Simpson, J. J. Younger, L. M. Baddour, F. F.
Barrett, D. M. Melton, and E. H. Beachey. 1985. Adherence of coagulase-
negative staphylococci to plastic tissue culture plates: a quantitative model
for the adherence of staphylococci to medical devices. J. Clin. Microbiol.
22:996–1006.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically. Seventh
edition: approved guideline M7-A7. Clinical and Laboratory Standards In-
stitute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Performance standards
for antimicrobial susceptibility testing. Eighteenth edition: approved infor-
mational supplement M100-S18. Clinical and Laboratory Standards Insti-
tute, Wayne, PA.
7. Corey, G. R. Studies of telavancin in cSSI. In Third International Symposium
on Resistant Gram-Positive Infections. Niagara-on-the-Lake, Ontario, Can-
ada; 10 October 2006.
8. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and
D. F. Sahm. 2008. Comparative surveillance study of telavancin activity
against recently collected gram-positive clinical isolates from across the
United States. Antimicrob. Agents Chemother. 52:2383–2388.
9. Gander, S., A. Kinnaird, and R. Finch. 2005. Telavancin: in vitro activity
against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337–
343.
10. Hegde, S. S., N. Reyes, R. Skinner, and S. Difuntorum. 2008. Efficacy of
telavancin in a murine model of pneumonia induced by methicillin-suscep-
tible Staphylococcus aureus. J. Antimicrob. Chemother. 61:169–172.
11. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K.
Kaniga, J. Pace, R. Thomas, J. P. Shaw, G. Obedencio, and J. K. Judice.
2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal
agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:
3043–3050.
12. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E.
Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass,
D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multi-
functional lipoglycopeptide, disrupts both cell wall synthesis and cell mem-
brane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob.
Agents Chemother. 49:1127–1134.
13. Krause, K. M., M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and
B. M. Benton. 2008. In vitro activity of telavancin against resistant gram-
positive bacteria. Antimicrob. Agents Chemother. 52:2647–2652.
14. LaPlante, K. L., and L. A. Mermel. 2007. In vitro activity of daptomycin and
vancomycin lock solutions on staphylococcal biofilms in a central venous
catheter model. Nephrol. Dial. Transplant. 22:2239–2246.
15. Leadbetter, M. R., S. M. Adams, B. Bazzini, P. R. Fatheree, D. E. Karr,
K. M. Krause, B. M. Lam, M. S. Linsell, M. B. Nodwell, J. L. Pace, K. Quast,
J. P. Shaw, E. Soriano, S. G. Trapp, J. D. Villena, T. X. Wu, B. G. Chris-
tensen, and J. K. Judice. 2004. Hydrophobic vancomycin derivatives with
improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot.
(Tokyo) 57:326–336.
16. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavan-
cin in a rabbit model of aortic valve endocarditis due to methicillin-resistant
Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Antimicrob. Agents Chemother. 49:3163–3165.
17. Mermel, L. A., B. M. Farr, R. J. Sherertz, I. Raad, N. O’Grady, J. S. Harris,
and D. E. Craven. 2001. Guidelines for the management of intravascular
catheter-related infections. Clin. Infect. Dis. 32:1249–1272.
18. Odenholt, I., E. Lowdin, and O. Cars. 2007. Pharmacodynamic effects of
telavancin against methicillin-resistant and methicillin-susceptible Staphylo-
coccus aureus strains in the presence of human albumin or serum and in an
in vitro kinetic model. Antimicrob. Agents Chemother. 51:3311–3316.
19. Reyes, N., R. Skinner, B. M. Benton, K. M. Krause, J. Shelton, G. P.
Obedencio, and S. S. Hegde. 2006. Efficacy of telavancin in a murine model
of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J.
Antimicrob. Chemother. 58:462–465.
20. Reyes, N., R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio,
A. Gough, M. Conner, and S. S. Hegde. 2005. Efficacy of telavancin (TD-
6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of
action, in a murine model of pneumonia induced by methicillin-resistant
Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344–4346.
21. Schumacher-Perdreau, F., C. Heilmann, G. Peters, F. Gotz, and G. Pulverer.
1994. Comparative analysis of a biofilm-forming Staphylococcus epidermidis
strain and its adhesion-positive, accumulation-negative mutant M7. FEMS
Microbiol. Lett. 117:71–78.
22. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere.
2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety
of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195–
201.
23. Stepanovic´, S., D. Vukovic´, I. Dakic´, B. Savic´, and M. Sˇvabic´-Vlahovic´. 2000.
A modified microtiter-plate test for quantification of staphylococcal biofilm
formation. J. Microbiol. Methods 40:175–179.
24. Stepanovic´, S., D. Vukovic´, V. Hola, G. Di Bonaventura, S. Djukic´, I. Cirk-
ovic´, and F. Ruzicka. 2007. Quantification of biofilm in microtiter plates:
overview of testing conditions and practical recommendations for assessment
of biofilm production by staphylococci. APMIS 115:891–899.
25. Stryjewski, M. E., V. H. Chu, W. D. O’Riordan, B. L. Warren, L. M. Dunbar,
D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere,
M. M. Kitt, and G. R. Corey. 2006. Telavancin versus standard therapy for
treatment of complicated skin and skin structure infections caused by gram-
positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862–
867.
26. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O’Riordan, D. Young, A.
Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L.
Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin
for the treatment of complicated skin and skin-structure infections caused by
gram-positive organisms. Clin. Infect. Dis. 46:1683–1693.
27. Stryjewski, M. E., W. D. O’Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M.
Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt,
C. H. Cabell, and G. R. Corey. 2005. Telavancin versus standard therapy for
treatment of complicated skin and soft-tissue infections due to gram-positive
bacteria. Clin. Infect. Dis. 40:1601–1607.
28. Stucki, A., P. Gerber, F. Acosta, M. Cottagnoud, and P. Cottagnoud. 2006.
Efficacy of telavancin against penicillin-resistant pneumococci and Staphylo-
coccus aureus in a rabbit meningitis model and determination of kinetic
parameters. Antimicrob. Agents Chemother. 50:770–773.
29. Xu, K. D., G. A. McFeters, and P. S. Stewart. 2000. Biofilm resistance to
antimicrobial agents. Microbiology 146(Pt. 3):547–549.
30. Yarwood, J. M., D. J. Bartels, E. M. Volper, and E. P. Greenberg. 2004.
Quorum sensing in Staphylococcus aureus biofilms. J. Bacteriol. 186:1838–
1850.
VOL. 53, 2009 TELAVANCIN ACTIVITY AGAINST BIOFILM-PRODUCING BACTERIA 3169
 o
n
 O
ctober 30, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
